• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4698277)   Today's Articles (226)
For: Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018;17:709-717. [PMID: 29848085 DOI: 10.1080/14740338.2018.1483330] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Number Cited by Other Article(s)
51
Russo CV, Saccà F, Paternoster M, Buonomo AR, Gentile I, Scotto R, Brescia Morra V, Mansueto G. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Mult Scler 2019;26:123-126. [DOI: 10.1177/1352458518813110] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
52
Buonomo AR, Saccà F, Zappulo E, De Zottis F, Lanzillo R, Gentile I, Carotenuto A, Borgia G, Russo CV. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. Mult Scler Relat Disord 2019;27:44-45. [DOI: 10.1016/j.msard.2018.09.031] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 09/21/2018] [Accepted: 09/30/2018] [Indexed: 11/24/2022]
PrevPage 2 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA